These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 25434585)

  • 21. Advantages of intensity modulated radiotherapy in recurrent T1-2 nasopharyngeal carcinoma: a retrospective study.
    Qiu S; Lu J; Zheng W; Xu L; Lin S; Huang C; Xu Y; Huang L; Pan J
    BMC Cancer; 2014 Nov; 14():797. PubMed ID: 25366703
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PET/CT-guided dose-painting versus CT-based intensity modulated radiation therapy in locoregional advanced nasopharyngeal carcinoma.
    Liu F; Xi XP; Wang H; Han YQ; Xiao F; Hu Y; He Q; Zhang L; Xiao Q; Liu L; Luo L; Li Y; Mo Y; Ma HZ
    Radiat Oncol; 2017 Jan; 12(1):15. PubMed ID: 28587681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is maximum primary tumor diameter still a prognostic factor in patients with nasopharyngeal carcinoma treated using intensity-modulated radiotherapy?
    Chen Y; Hu XF; Wang Y; Chen HY; Yang L; Liu LZ; Cui CY; Liu DS; Liang SB
    BMC Cancer; 2015 Apr; 15():305. PubMed ID: 25903652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term survival and late complications in intensity-modulated radiotherapy of locally recurrent T1 to T2 nasopharyngeal carcinoma.
    Tian YM; Guan Y; Xiao WW; Zeng L; Liu S; Lu TX; Zhao C; Han F
    Head Neck; 2016 Feb; 38(2):225-31. PubMed ID: 25244494
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical outcome for nasopharyngeal carcinoma with predominantly WHO II histology treated with intensity-modulated radiation therapy in non-endemic region of China.
    Zhao LN; Zhou B; Shi M; Wang JH; Xiao F; Xu M; Luo SQ; Xue Y; Li JP; Tan LN
    Oral Oncol; 2012 Sep; 48(9):864-9. PubMed ID: 22445296
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma.
    Peng G; Wang T; Yang KY; Zhang S; Zhang T; Li Q; Han J; Wu G
    Radiother Oncol; 2012 Sep; 104(3):286-93. PubMed ID: 22995588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of prepontine cistern invasion in nasopharyngeal carcinoma treated by intensity-modulated radiotherapy.
    Hung TM; Chen CC; Lin CY; Ng SH; Kang CJ; Huang SF; Liao CT; Fan KH; Wang HM; Chang JT
    Oral Oncol; 2014 Mar; 50(3):228-33. PubMed ID: 24394562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A retrospective study comparing the outcomes and toxicities of intensity-modulated radiotherapy versus two-dimensional conventional radiotherapy for the treatment of children and adolescent nasopharyngeal carcinoma.
    Qiu WZ; Peng XS; Xia HQ; Huang PY; Guo X; Cao KJ
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1563-1572. PubMed ID: 28342002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of dosimetric inadequacy on local control and toxicities in the patients with T4 nasopharyngeal carcinoma extending into the intracranial space and treated with intensity-modulated radiotherapy plus chemotherapy.
    Xue F; Hu CS; He XY
    Chin J Cancer; 2017 Sep; 36(1):76. PubMed ID: 28931426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor Regression and Patterns of Distant Metastasis of T1-T2 Nasopharyngeal Carcinoma with Intensity-Modulated Radiotherapy.
    Wu MY; He XY; Hu CS
    PLoS One; 2016; 11(4):e0154501. PubMed ID: 27119991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the seventh and eighth editions of the UICC/AJCC staging system for nasopharyngeal carcinoma: analysis of 1317 patients treated with intensity-modulated radiotherapy at two centers.
    Yang XL; Wang Y; Liang SB; He SS; Chen DM; Chen HY; Lu LX; Chen Y
    BMC Cancer; 2018 May; 18(1):606. PubMed ID: 29843648
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term Survivals, Toxicities and the Role of Chemotherapy in Early-Stage Nasopharyngeal Carcinoma Patients Treated with Intensity-Modulated Radiation Therapy: A Retrospective Study with 15-Year Follow-up.
    Wang L; Miao J; Huang H; Chen B; Xiao X; Zhu M; Liang Y; Xiao W; Huang S; Peng Y; Deng X; Lv X; Xia W; Xiang Y; Guo X; Han F; Zhao C
    Cancer Res Treat; 2022 Jan; 54(1):118-129. PubMed ID: 34098625
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reirradiation with intensity-modulated radiotherapy for locally recurrent T3 to T4 nasopharyngeal carcinoma.
    Chan OS; Sze HC; Lee MC; Chan LL; Chang AT; Lee SW; Hung WM; Lee AW; Ng WT
    Head Neck; 2017 Mar; 39(3):533-540. PubMed ID: 27898191
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic factors and failure patterns in non-metastatic nasopharyngeal carcinoma after intensity-modulated radiotherapy.
    Mao YP; Tang LL; Chen L; Sun Y; Qi ZY; Zhou GQ; Liu LZ; Li L; Lin AH; Ma J
    Chin J Cancer; 2016 Dec; 35(1):103. PubMed ID: 28031050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-Term Results of Intensity-Modulated Radiotherapy for T4 Nasopharyngeal Carcinoma: New Insight into the Value of Concurrent Chemotherapy.
    Kong F; Zhai R; Huang J; Ying H; Hu C
    Cancer Invest; 2021 Sep; 39(8):645-652. PubMed ID: 34182848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ten-year survival outcomes for patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy: An analysis of 614 patients from a single center.
    Wu LR; Liu YT; Jiang N; Fan YX; Wen J; Huang SF; Guo WJ; Bian XH; Wang FJ; Li F; Song D; Wu JF; Jiang XS; Liu JY; He X
    Oral Oncol; 2017 Jun; 69():26-32. PubMed ID: 28559017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intensity-modulated radiotherapy for elderly patients with nasopharyngeal carcinoma.
    Cao C; Hu Q; Chen X
    Head Neck; 2018 Mar; 40(3):590-595. PubMed ID: 29155480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Propensity score matching analysis of a phase II study on simultaneous modulated accelerated radiation therapy using helical tomotherapy for nasopharyngeal carcinomas.
    Du L; Zhang XX; Feng LC; Qu BL; Chen J; Yang J; Liu HX; Xu SP; Xie CB; Ma L
    BMC Cancer; 2017 Aug; 17(1):582. PubMed ID: 28851315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The challenge in treating locally recurrent T3-4 nasopharyngeal carcinoma: the survival benefit and severe late toxicities of re-irradiation with intensity-modulated radiotherapy.
    Tian YM; Huang WZ; Yuan X; Bai L; Zhao C; Han F
    Oncotarget; 2017 Jun; 8(26):43450-43457. PubMed ID: 28427216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term late toxicities and quality of life for survivors of nasopharyngeal carcinoma treated with intensity-modulated radiotherapy versus non-intensity-modulated radiotherapy.
    Huang TL; Chien CY; Tsai WL; Liao KC; Chou SY; Lin HC; Dean Luo S; Lee TF; Lee CH; Fang FM
    Head Neck; 2016 Apr; 38 Suppl 1():E1026-32. PubMed ID: 26041548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.